This site is intended for healthcare professionals
Evidence is uncertain on the benefits of analgesics for low back pain
A systematic review and meta-analysis found low or very low confidence in the evidence for pain reduction with aceclofenac plus tizanidine, tolperisone, pregabalin and 14 other drugs than placebo. A moderate to very low confidence was seen for a rise in adverse events with acetaminophen plus sustained-release tramadol, acetaminophen plus tramadol and baclofen than placebo.
First-ever dietary recommendations issued for patients with rheumatism
A multidisciplinary group issued eight principles and nine recommendations for patients with chronic inflammatory rheumatic diseases. They advised weight loss for overweight patients, following a Mediterranean diet, and omega-3 supplementation to relieve symptoms. They advised against gluten-free, vegan, or vegetarian diets, fasting, and eliminating dairy from the diet.
Osteoporosis treatments could lower mortality after fractures
A real-world mega-data study on over 46,000 subjects suggested that alendronate/risedronate, denosumab, and zoledronic acid treatments were associated with significantly reduced mortality after fractures compared to raloxifene and bazedoxifene treatments. People aged over 65 years who were taking the long-acting zoledronic acid treatment had the lowest mortality.
Guidelines for advice on timing for elective knee or hip arthroplasty
ACR and AAHKS's guidelines say there is no evidence to delay surgery to test the effectiveness of new nonsurgical therapies. Patients with symptomatic arthritis who have had failed nonsurgical therapies should directly proceed for surgical treatments. Diabetic or nicotine-dependent patients should delay surgery until their glucose levels and dependence are controlled.
American College of Rheumatology
Running does not raise the chances of developing arthritis
An electronic survey with 30 questions involving over 3800 marathon runners revealed that the prevalence of knee/hip arthritis among them was 7.3%. Prior knee/hip injuries or surgeries, increasing age, BMI, and family history of arthritis were risk factors for arthritis. The findings suggested no link between cumulative running history and the risk of developing arthritis.
Do potatoes, brinjals, peppers elevate arthritis pain?
A rheumatologist explains that these "nightshade vegetables" contain a bitter-tasting chemical compound called solanine. It can irritate the gut and start inflammation in the gut, which can also increase joint pain as the gut and musculoskeletal system are intricately linked. But, evidence is limited to suggest eliminating them from the diet could reduce arthritis pain.
Study suggests best non-opioid drugs for lower back pain
An analysis of 18 randomized studies revealed that a combination of NSAIDs and a muscle relaxer was effective in reducing the disability and pain due to lower back pain. Additionally, combining acetaminophen with an NSAID was linked to a higher improvement than taking an NSAID alone. Taking acetaminophen alone also did not lower the pain significantly.
Running may not reduce the thickness of cartilage
A systematic review of studies analysed cartilage thickness after running in immediate and delayed settings using MRI. It revealed that there is only very low certainty evidence to suggest running reduces the volume, thickness, and relaxation time of tibiofemoral and patellofemoral cartilage immediately. Moreover, the changes in knee cartilage were minimal and transient.
ACP advises bisphosphonates for treating osteoporosis
Bisphosphonates are recommended as initial treatment for postmenopausal women and males with osteoporosis to reduce fracture risk. Bisphosphonates were found to have the most favourable risk-benefit profile, patient preferences and values, and cost among the drugs evaluated by the experts. The guidelines also highlight exercise, counselling, and lifestyle changes.
American College of Physicians
FDA approves abaloparatide for treating men at risk of fractures
TYMLOS® (abaloparatide) is a peptide analog related to parathyroid hormone. It is approved for treating men with osteoporosis to increase their bone mineral density to prevent fractures. The drug was approved in 2017 to treat postmenopausal women with osteoporosis. It is contraindicated in those with hypersensitivity reactions due to the drug or formulation components.